

## ATMP HYBRID CONFERENCE



## ATMPs - An Irish Perspective Delivered by Eminent Global ATMP Experts

Friday 26<sup>th</sup> November 2021 Time: 8:00am – 4:30pm (Irish Standard Time) Crowne Plaza Hotel, Blanchardstown and Online

8:00 – 9:00	Registration: Networking and Breakfast	mej Crowne Plaza notel, blanchardstown and Online
9:00 – 9:20	Opening	Moderated by Valerie Mulholland, Senior Consultant at GMP Services.
	Welcome from PDA Ireland President	Ann McGee, MD/CEO at MIAS Pharma Limited.
	<b>Keynote Address -</b> "ATMPS represent the next wave of therapeutics with global research powering ahead – Ireland needs to embrace this and use it to enhance the contribution that the biopharma sector makes to the Irish economy as well as delivering solutions to unmet and existing medical needs"	Matt Moran, Director at BioPharmaChem Ireland.
9:20 – 9:40	Contamination Control Strategy for Cell Therapy Manufacturing Facility.	Bertie Daly, Takeda Cell Therapy Facility Lead Dr. Aidan Harrington, Senior Consultant DPS, Ireland.
9:45 – 10:05	mRNA Vaccines - An Overview of the Manufacturing Challenges and Bottlenecks.	Catherine Jomary PhD, formerly Biogen, Novartis, Takeda, Lonza.
10:10 - 10:30	Advanced Kinetic Degradation and Thermodynamic Modelling in Biopharmaceuticals.	<b>Kevin O'Connor,</b> Technical Lead MSAT – Sanofi. <b>Warren Roche</b> Statistician MSAT – Sanofi.
10:35 – 10:55	A Fully Integrated Ecosystem for Manufacturing Gene Therapies from Clinical through Commercialization.	<b>Brian O'Connor,</b> Director of Quality Assurance, MeiraGTx Ireland
11:00 - 11:20	Coffee Break and Networking	
11:20 – 12:00	Panel Discussion and Audience Q&A on Topics Discussed by Speakers	Chaired by <b>Kate Coleman,</b> Senior Director/Principal Consultant PharmaLex.
12:00 - 13:00	Lunch	
13:00 – 13:25	An update on the work of the Irish Cell and Gene Therapy and Vaccine manufacturing (CGT&V) Forum.	<b>Professor Niall Barron,</b> NIBRT/UCD Professor of Biochemical Engineering.
13:30 – 13:55	Unlocking the Promise of Precision Medicine in Ireland - Delivering Cell Therapies In-Country to 200 Patients per Year by 2027.	<b>Gary McAuslan,</b> Co-founder & CEO aCGT Vector Managing Director.
14:00 – 14:35	New Momentum for Advanced Therapies: How Can Regulators Help?	<b>Dr. Christian K Schneider</b> Head of Biopharma Excellence & Chief Medical Officer <b>Kate Coleman</b> , Senior Director/Principal Consultant, Quality Management and Compliance
14:40 – 15:00	Coffee break and Networking	
15:00 - 15:45	Panel Discussion and Audience Q&A on Topics Discussed by Speakers	Chaired by <mark>Dुट, Aidan Harrington.</mark>
15:45 – 16:00	Close by Moderator	Valerie Mulholland, Senior Consultant at GMP Services.
	Closing Comments by PDA Ireland President	Ann McGee, MD/CEO at MIAS Pharma Limited.
16:00 - 16:30	Networking	



MAIN SPONSOR
Integrated Project Services
SPONSORS













